Posted by Michael Wonder on 02 Jun 2020
European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma
2 June 2020 - EC approval based on data from first randomised Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone.
The European Commission has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
